Page 4 - C Diff News Today

Results from the study found a high risk of CDI associated with clindamycin and low risk associated with doxycycline and minocycline, also highlighting variation in CDI risk within and between classes of antibiotics.

Why do nonsteroidal anti-inflammatory drugs (NSAIDs) exacerbate gastrointestinal infections by Clostridioides difficile, the leading cause of antibiotic-associated diarrhea worldwide?

Candace Cotto, RN, and Andrew Skinner, MD, discuss barriers to use of FMTs in managing CDI, highlighting clinician and patient education.

Experts comment on insurance coverage as a factor for the broader use of FMTs for the management of CDI.

Experts discuss new and emerging treatments the management of CDI, highlighting the phase 3 trials for SER 109.

Antibiotics no longer work against many infections due to MDROs, causing more illness and death. What is antimicrobial resistance (AMR) doing to the environment?

Joseph Reilly, BS, PharmD, BCGP, and Andrew Skinner, MD, discuss the potential benefits of using live-jslm early on to treat CDI, as well as the implications of this new treatment.

Joseph Reilly, BS, PharmD, BCGP, provides an overview of a new FDA-approved FMT therapy, live-jslm for the treatment of CDI.

Using a diverse human gut community, researchers investigated how gut microbiota interspecies interactions affected the response of Clostridioides difficile to vancomycin and metronidazole.

Andrew Skinner, MD, reviews challenges in managing CDI, as well as the treatment guidelines from IDSA, SHEA, and ACG.